Wall Street analysts forecast that Alphabet (GOOGL) will report quarterly earnings of $2.58 per share in its upcoming release, pointing to a year-over-year increase of 20%. It is anticipated that revenues will amount to $94.7 billion, exhibiting an increase of 16% compared to the year-ago quarter.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ...

Analysts on Wall Street project that Aflac (AFL) will announce quarterly earnings of $1.71 per share in its forthcoming report, representing an increase of 9.6% year over year. Revenues are projected to reach $4.48 billion, increasing 3.8% from the same quarter last year.Over the last 30 days, there has been a downward revision of 1.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over ...

Core Viewpoint - Analysts project that Modine (MOD) will report quarterly earnings of $0.99 per share, reflecting a year-over-year increase of 7.6%, with revenues expected to reach $763.38 million, a 23.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 2.6% higher in the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Key Metrics - Analysts estimate 'Net Sales- Performance Technologies' to be $252.69 million, a decrease of 3.6% from the previous year [5]. - 'Net Sales- Climate Solutions' is expected to reach $522.14 million, representing an increase of 44.7% year-over-year [5]. - 'Adjusted EBITDA- Climate Solutions' is projected at $88.77 million, up from $75.70 million in the prior year [5]. - The consensus for 'Adjusted EBITDA- Performance Technologies' is $35.22 million, compared to $28.40 million from the previous year [6]. Stock Performance - Over the past month, Modine shares have increased by 32.4%, while the Zacks S&P 500 composite has only increased by 0.9% [6]. - Modine currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [6].

Core Viewpoint - Advanced Drainage Systems (WMS) is anticipated to report a year-over-year increase in earnings despite a decline in revenues for the quarter ending December 2025, with actual results being crucial for stock price impact [1][2]. Earnings Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $1.11 per share, reflecting a +1.8% change year-over-year, while revenues are projected at $686.55 million, down 0.6% from the previous year [3]. - The consensus EPS estimate has been revised 0.71% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +0.98%, suggesting analysts are optimistic about the company's earnings prospects [11]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which enhances predictive power [8]. Historical Performance - In the last reported quarter, Advanced Drainage exceeded the expected earnings of $1.7 per share by delivering $1.97, resulting in a surprise of +15.88% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Investment Considerations - While an earnings beat can influence stock movement, other factors may also affect investor sentiment, making it essential to consider the broader context [14][16]. - Monitoring the Earnings ESP and Zacks Rank can help identify stocks with higher chances of beating earnings expectations [15].

Core Viewpoint - SEI Investments (SEIC) has shown a 5% gain over the past four weeks, with a mean price target of $109.5 indicating a potential upside of 27.2% from its current price of $86.1 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $8.66, where the lowest estimate is $102.00 (an 18.5% increase) and the highest is $117.00 (a 35.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about SEIC's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 0.5% increase in the Zacks Consensus Estimate over the past month [11][12] - SEIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a commonly referenced metric, they should be approached with skepticism as they may not reliably indicate actual stock price movements [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8]

Core Viewpoint - Amgen (AMGN) is expected to report quarterly earnings of $4.74 per share, a decline of 10.7% year-over-year, with revenues projected at $9.46 billion, reflecting a 4.2% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.1% over the past 30 days, indicating analysts have adjusted their projections positively [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between these revisions and short-term stock price performance [3]. Revenue and Product Sales Projections - Analysts predict 'Revenue- Other revenues' will reach $402.12 million, an increase of 8.7% from the prior-year quarter [5]. - 'Revenue- Product sales' is expected to be $9.04 billion, reflecting a 3.7% increase year-over-year [5]. - 'Product Sales- Vectibix- Total' is projected at $279.69 million, indicating a 13.7% increase from the previous year [5]. Specific Product Sales Estimates - 'Product Sales- Enbrel- Total' is estimated at $649.46 million, showing a significant decline of 36% year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is projected at $56.02 million, down 22.2% from the year-ago quarter [6]. - 'Product Sales- Neulasta- ROW' is expected to reach $19.40 million, reflecting a 25.4% decline [6]. - 'Product Sales- BLINCYTO- ROW' is estimated at $152.62 million, an increase of 12.2% year-over-year [7]. - 'Product Sales- Repatha- U.S.' is projected at $442.32 million, indicating a substantial increase of 40.4% from the previous year [7]. - 'Product Sales- Repatha- ROW' is expected to be $360.19 million, reflecting a 23.8% increase [8]. - 'Product Sales- BLINCYTO- U.S.' is projected at $287.58 million, indicating a 17.4% increase [8]. - 'Product Sales- KYPROLIS- U.S.' is expected to reach $228.82 million, showing a slight decline of 3% year-over-year [8]. - 'Product Sales- KYPROLIS- ROW' is projected at $130.37 million, reflecting a 4.1% decline [9]. Stock Performance - Amgen shares have increased by 4.6% over the past month, outperforming the Zacks S&P 500 composite, which has risen by 0.8% [9].

Wall Street analysts forecast that Electronic Arts (EA) will report quarterly earnings of $4.77 per share in its upcoming release, pointing to a year-over-year increase of 68.6%. It is anticipated that revenues will amount to $2.86 billion, exhibiting an increase of 28.9% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course o ...

Core Viewpoint - Merck (MRK) is expected to report quarterly earnings of $2.04 per share, an 18.6% increase year-over-year, with revenues projected at $16.19 billion, reflecting a 3.6% increase compared to the same period last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 85.2%, indicating a significant reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Key Metrics Projections - Analysts estimate 'Sales- Vaccines- Vaxneuvance' at $178.52 million, a 10.9% increase year-over-year [5]. - 'Sales- Oncology- Keytruda' is projected to reach $8.31 billion, reflecting a 6.1% increase from the previous year [5]. - 'Sales- Oncology- Alliance revenue- Lenvima' is expected to be $243.71 million, indicating a 4.4% decrease year-over-year [5]. Additional Sales Estimates - 'Sales- Vaccines- Gardasil' is projected at $1.04 billion, showing a significant decline of 32.9% year-over-year [6]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is expected to reach $418.39 million, a 9.5% increase year-over-year [6]. - 'Sales- Oncology- Keytruda - International' is estimated at $3.39 billion, reflecting a 13.3% increase year-over-year [6]. Further Sales Insights - 'Sales- Diabetes- Janumet - U.S.' is forecasted at $69.57 million, a decrease of 23.6% year-over-year [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is expected to be $176.62 million, showing a slight decrease of 0.2% [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is projected at $211.75 million, indicating a 13.2% increase year-over-year [8]. Market Performance - Merck shares have recorded a return of +1.6% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change [9]. - Based on its Zacks Rank 4 (Sell), Merck is expected to underperform the overall market in the upcoming period [10].

Company Overview - Richtech (RR) shares increased by 44.6% to $5.51, with a notable trading volume, following a strategic partnership with Microsoft to integrate agentic AI into its robotic platforms, enhancing growth prospects [1] - The company is expected to report a quarterly loss of $0.02 per share, reflecting a year-over-year improvement of 50%, with anticipated revenues of $1.91 million, up 51.6% from the previous year [2] Earnings Estimates - The consensus EPS estimate for Richtech has been revised 33.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - Empirical research suggests a strong correlation between earnings estimate revisions and near-term stock price movements, highlighting the importance of monitoring these trends [2][3] Industry Context - Richtech is part of the Zacks Technology Services industry, which includes Amprius Technologies (AMPX), another player in the sector that saw a 6.2% increase in its stock price, closing at $11.58, and has returned 37.6% over the past month [3] - Amprius has an unchanged consensus EPS estimate of -$0.04 for its upcoming report, representing a 60% improvement from the previous year, and currently holds a Zacks Rank of 3 (Hold) [4]

Core Viewpoint - Analysts project that The Hartford Insurance Group (HIG) will report quarterly earnings of $3.17 per share, reflecting a year-over-year increase of 7.8%, with revenues expected to reach $5.14 billion, up 7.4% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.4% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - The consensus estimate for 'Revenue- Earned Premium- Personal Insurance' is $946.67 million, indicating a 4.5% increase year-over-year [5]. - Analysts expect 'Revenue- Property & Casualty- Earned Premium' to reach $4.53 billion, reflecting a 7.6% year-over-year change [5]. - The estimated 'Revenue- Property and Casualty- Net investment income' is projected at $585.46 million, showing a 4.2% increase year-over-year [6]. - 'Revenue- Net premiums earned' is expected to be $6.16 billion, indicating a 6% increase from the prior-year quarter [7]. - The average prediction for 'Revenue- Hartford Funds - Total' is $283.00 million, representing a 4.1% increase from the year-ago quarter [8]. Key Metrics - The 'Personal Insurance - Loss and loss adjustment expense ratio' is expected to be 64.0%, up from 59.3% in the same quarter last year [8]. - The 'Personal Insurance - Expense ratio' is forecasted to remain at 26.5%, consistent with the previous year's figure [9]. - The 'Personal Insurance - Combined ratio' is projected at 90.5%, compared to 85.8% in the same quarter of the previous year [9]. - The 'Personal Insurance - Underlying combined ratio' is estimated to be 89.5%, slightly improved from 90.2% a year ago [10]. Stock Performance - Shares of The Hartford Insurance Group have shown a return of -5.8% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [11].